1461093500-3d702439-2e32-4218-bc50-6caac7043774

1. A powder for oral suspension comprising greater than 4.2% by weight of cefdinir.
2. A powder for oral suspension comprising about 6% to about 10% by weight of cefdinir.
3. A powder for oral suspension comprising at least 8.4% by weight cefdinir.
4. A powder for oral suspension comprising
(a) at least 8.4% by weight cefdinir;
(b) a diluent; and
(c) a buffering agent.
5. A powder for oral suspension of claim 4 wherein the diluent is selected from the group consisting of sucrose, sorbitol, xylitol, dextrose, fructose, malitol, sugar potassium, aspartame, saccharin, saccharin sodium, and mixtures thereof.
6. A powder for oral suspension of claim 5 wherein the diluent is sucrose.
7. A powder for oral suspension of claim 4 wherein the buffering agent is selected from the group consisting of citric acid, sodium citrate, sodium phosphate, potassium citrate, and mixtures thereof.
8. A powder for oral suspension of claim 7 wherein the buffering agent is a mixture of citric acid and sodium citrate.
9. A powder for oral suspension comprising:
(a) about 8.4% by weight cefdinir;
(b) about 89.2% by weight diluent;
(c) about 0.26% by weight buffering agent;
(d) about 0.16% by weight preservative;
(e) about 0.33% by weight viscosity enhancer;
(f) about 1.31% by weight flavoring agent;
(g) about 0.07% glidant; and
(h) about 0.35% lubricant.
10. A powder for oral suspension of claim 9 wherein the diluent is selected from the group consisting of sucrose, sorbitol, xylitol, dextrose, fructose, malitol, sugar potassium, aspartame, saccharin, saccharin sodium, and mixtures thereof.
11. A powder for oral suspension of claim 10 wherein the diluent is sucrose.
12. A powder for oral suspension of claim 9 wherein the buffering agent is selected from the group consisting of citric acid, sodium citrate, sodium phosphate, potassium citrate, and mixtures thereof.
13. A powder for oral suspension of claim 12 wherein the buffering agent is a mixture of citric acid and sodium citrate.
14. A powder for oral suspension of claim 9 wherein the preservative is selected from the group consisting of sodium benzoate, benzoic acid, ethylenediaminetetraacetic acid, sorbic acid, benzethonium chloride, benzalkonium chloride, bronopol, butyl paraben, methyl paraben, ethylparaben, propyl paraben, thiomerosol, sodium propionate, chlorhexidine, chlorobutanol, chlorocresol, cresol, imidurea, phenol, phenylmercuric salts, potassium sorbate, propylene glycol, and mixtures thereof.
15. A powder for oral suspension of claim 14 wherein the preservative is sodium benzoate.
16. A powder for oral suspension of claim 9 wherein the viscosity enhancing agent is selected from the group consisting of xantham gum, guar gum, acacia, povidone, alginic acid, sodium alginate, propylene glycol alginate, carbomer, carboxymethylcellulose calcium, carboxymethylcellulose sodium, ethylcellulose, gelatin, ethylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polydextrose, carrageenan, methylcellulose, sucrose, sorbitol, xylitol, dextrose, fructose, malitol, sugar, sodium alginate, tragacanth, hydroxypropyl methylcellulose, bentonite, a polyvinyl alcohol, cetearyl alcohol, colloidal silicon dioxide, and mixtures thereof.
17. A powder for oral suspension of claim 16 wherein the viscosity enhancing agent is a mixture of xantham gum and guar gum.
18. A powder for oral suspension of claim 9 wherein the glidant is selected from the group consisting of colloidal silicon dioxide, talc, fumed silica, magnesium stearate, calcium stearate, magnesium trisilicate, powdered cellulose, starch, tribasic calcium phosphate, and mixtures thereof.
19. A powder for oral suspension of claim 18 wherein the glidant is colloidal silicon dioxide.
20. A powder for oral suspension of claim 9 wherein the lubricant is selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, magnesium oxide, stearic acid, sodium stearyl fumarate, sodium lauryl stearate, hydrogenated vegetable oil, corn starch, colloidal silicon dioxide, talc, and mixtures thereof.
21. A powder for oral suspension of claim 20 wherein the lubricant is magnesium stearate.
22. A powder for oral suspension comprising:
(a) about 8.36% by weight cefdinir;
(b) about 89.16% by weight sucrose;
(c) about 0.16% by weight citric acid;
(d) about 0.10% by weight sodium citrate;
(e) about 0.16% by weight sodium benzoate;
(f) about 0.16% by weight xantham gum;
(g) about 0.16% by weight guar gum;
(h) about 1.31% by weight flavoring agent;
(i) about 0.06% colloidal silicon dioxide; and
(j) about 0.35% magnesium stearate.
23. A method of treating acute bacterial otitis media, pharyngitis and tonsillitis with a oral suspension of cefdinir wherein said suspension is made by reconstituting a powder comprising greater than 4.2% by weight of cefdinir.
24. A method of treating acute bacterial otitis media, pharyngitis and tonsillitis with a oral suspension of cefdinir wherein said suspension is made by reconstituting a powder comprising at least 8.4% cefdinir.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of the following formula:
M-(BM)n

wherein
M is a radionuclide that is a positron emitter;
n is an integer from 1to 10; and
BM is an SR-A antagonist of formula:
wherein
R1 is independently selected from: H, R1-benzamido, R1-benzylether, R1-benzylamino, amino, fluoralkyl, halo, cyano, nitro, aryloxyl, haloaryl, aryl, alkoxy, an 1,2-benzo; or R1 represents a fused ring forming naphthalene moiety with the six membered aryl ring it substitutes;
R2 is a direct bond to M; and
m is an integer from 1 to 4;
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 wherein said radionuclide is 18F or 11C.
3. The compound of claim 2 wherein said radionuclide is 18F.
4. A compound of the following formula:
M-(BM)n

wherein,
M is radionuclide that is a positron emitter;
n is an integer from 1 to 10; and
BM is an SR-A antagonist of formula:
wherein
R1 is independently selected from: H, R1-benzamido, R1-benzylether, R1-benzylamino, amino, fluoralkyl, halo, cyano, nitro, aryloxyl, haloaryl, aryl, alkoxy, an 1,2-benzo; or R represents a fused ring forming naphthalene moiety with the six membered aryl ring it substitutes;
R2 is a direct bond to M;
m is an integer from 1 to 4;
M\u2032 is a metal ion selected from Fe(III, Os(III), Co(III), Ni(II), Cu(II), Mn(IJ), o Al(III);
M\u2033 is a metal-containing moiety selected from: V\u2550O, MO\u2550O, Re\u2550O, or Tc\u2550O; d
L is a coligand selected from: trialkylphosphine, triarylphosphine, triarylyalkylphosphine, pyridine or pyridine analog with appropriate substituent on the pyridine ring;
or a pharmaceutically acceptable salt thereof.
5. The compound of claim 4 wherein:
M\u2032 is a metal ion selected from Fe(III, Os(III), Co(III), Ni(II), or Cu(II); and M\u2033 is a metal-containing moiety selected from: V\u2550O, Mo\u2550O, or Re\u2550O.
6. The compound of claim 5 wherein said radionuclide is 18F or 11C.
7. The compound of claim 6 wherein said radionuclide is 18F.
8. A method to diagnose a cardiovascular disease in a patient comprising administering to the patient in need of such diagnosis an effective amount of a compound of claim 1 and detecting the presence of the compound.
9. The method of claim 8 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
10. A method to diagnose a cardiovascular disease in a patient comprising administering to the patient in need of such diagnosis an effective amount of a compound of claim 3 and detecting the presence of the compound.
11. The method of claim 10 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
12. A method to monitor a cardiovascular disease in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 1 and detecting the presence of the compound.
13. The method of claim 12 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
14. A method to monitor a cardiovascular disease in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 3 and detecting the presence of the compound.
15. The method of claim 14 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
16. A method to monitor the progression of an atherosclerotic lesion in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 1 and detecting the presence of the compound.
17. A method to detect vulnerable plaque comprising administering to the patient in need of such detection a compound of claim 1 and detecting the presence of the compound.
18. A method to monitor the progression of an atherosclerotic lesion in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 3 and detecting the presence of the compound.
19. A method to detect vulnerable plaque comprising administering to the patient in need of such detection a compound of claim 3 and detecting the presence of the compound.
20. The method of claim 8 wherein the detection comprises positron emission tomography.
21. The method of claim 10 wherein the detection comprises positron emission tomography.
22. A method to diagnose a cardiovascular disease in a patient comprising administering the patient in need of such diagnosis an effective amount of a compound of claim 4 and detecting the presence of the compound.
23. The method of claim 22 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
24. A method to diagnose a cardiovascular disease in a patient comprising administering the patient in need of such diagnosis an effective amount of a compound of claim 7 and detecting the presence of the compound.
25. The method of claim 24 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
26. A method to monitor a cardiovascular disease in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 4 and detecting the presence of the compound.
27. The method of claim 26 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
28. A method to monitor a cardiovascular disease in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 7 and detecting the presence of the compound.
29. The method of claim 28 wherein the cardiovascular disease is selected from: atherosclerosis, vulnerable plaque, coronary artery disease, renal disease, thrombosis, transient ischemia due to clotting, stroke, myocardial infarction, organ transplant, organ failure and hypercholesterolemia.
30. A method to monitor the progression of an atherosclerotic lesion in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 4 and detecting the presence of the compound.
31. A method to monitor the progression of an atherosclerotic lesion in a patient comprising administering to the patient in need of such monitoring an effective amount of a compound of claim 7 and detecting the presence of the compound.
32. A method to detect vulnerable plaque comprising administering to the patient in need of such detection a compound of claim 4 and detecting the presence of the compound.
33. A method to detect vulnerable, plaque comprising administering to the patient in need of such detection a compound of claim 7 and detecting the presence of the compound.
34. The method of claim 22 wherein the detection comprises positron emission tomography.
35. The method of claim 24 wherein the detection comprises positron emission tomography.
36. A pharmaceutical composition comprising a predetermined quantity of a compound of claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
37. The pharmaceutical composition of claim 36 further comprising an effective amount of a stabilizer.
38. The pharmaceutical composition of claim 37 wherein the stabilizer is selected from the group: ascorbic acid, benzyl alcohol, gentisic acid or a metal salt thereof, p-aminobenzoic acid or a salt thereof, cysteamine, 5-amino-2-hydroxybenzoic acid or a metal salt thereof; nicotinic acid or a metal salt thereof, nicotinamide, a polyhydroxylated aromatic compound, an aromatic amine, and a hydroxylated aromatic amine.
39. A pharmaceutical composition comprising a predetermined quantity of a compound of claim 3, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
40. The pharmaceutical composition of claim 39 further comprising an effective amount of a stabilizer.
41. The pharmaceutical composition of claim 40 wherein the stabilizer is selected from the group: ascorbic acid, benzyl alcohol, gentisic acid or a metal salt thereof, p-aminobenzoic acid or a salt thereof, cysteamine, 5-amino-2-hydroxybenzoic acid or a metal salt thereof, nicotinic acid or a metal salt thereof, nicotinamide, a polyhydroxylated aromatic compound, an aromatic amine, and a hydroxylated aromatic amine.
42. A pharmaceutical composition comprising a predetermined quantity of a compound of claim 4 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
43. The pharmaceutical composition of claim 42 further comprising an effective amount of a stabilizer.
44. The pharmaceutical composition of claim 43 wherein the stabilizer is selected from the group: ascorbic acid, benzyl alcohol, gentisic acid or a metal salt thereof, p-aminobenzoic acid or a salt thereof, cysteamine, 5-amino-2-hydroxybenzoic acid or a metal salt thereof, nicotinic acid or a metal salt thereof, nicotinamide, a polyhydroxylated aromatic compound, an aromatic amine, and a hydroxylated aromatic amine.
45. A pharmaceutical composition comprising a predetermined quantity of a compound of claim 7, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
46. The pharmaceutical composition of claim 45 further comprising an effective amount of a stabilizer.
47. The pharmaceutical composition of claim 46 wherein the stabilizer is selected from the group: ascorbic acid, benzyl alcohol, gentisic acid or a metal salt thereof, p-aminobenzoic acid or a salt thereof, cysteamine, 5-amino-2-hydroxybenzoic acid or a metal salt thereof, nicotinic acid or a metal salt thereof, nicotinamide, a polyhydroxylated aromatic compound, an aromatic amine, and a hydroxylated aromatic amine.
48. A kit comprising a sealed vial comprising a predetermined quantity of a compound of claim 1 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
49. The kit of claim 48 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
50. A kit comprising a sealed vial comprising a predetermined quantity of a compound of claim 3 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
51. The kit of claim 50 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
52. A kit comprising a sealed vial comprising a predetermined quantity of a compound of claim 4 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
53. The kit of claim 52 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
54. A kit comprising a sealed vial comprising a predetermined quantity of a compound of claim 7 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier or diluent.
55. The kit of claim 54 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
56. A kit comprising (a) a first vial comprising a predetermined quantity of a compound of claim 1, or a pharmaceutically acceptable salt thereof; and (b) a second vial comprising a pharmaceutically acceptable carrier or diluent.
57. The kit of claim 56 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
58. A kit comprising (a) a first vial comprising a predetermined quantity of a compound of claim 3, or a pharmaceutically acceptable salt thereof; and (b) a second vial comprising a pharmaceutically acceptable carrier or diluent.
59. The kit of claim 58 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
60. A kit comprising (a) a first vial comprising a predetermined quantity of a compound of claim 4, or a pharmaceutically acceptable salt thereof; and (b) a second vial comprising a pharmaceutically acceptable carrier or diluent.
61. The kit of claim 60 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.
62. A kit comprising (a) a first vial comprising a predetermined quantity of a compound of claim 7, or a pharmaceutically acceptable salt thereof; and (b) a second vial comprising a pharmaceutically acceptable carrier or diluent.
63. The kit of claim 62 further comprising at least one of a reducing agent, a bulking agent, or a weak transfer ligand.